FDA Approves New Oral Therapy for CLL
The U.S. Food and Drug Administration has approved the combination of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL). Supported by data from the Phase 3 AMPLIFY trial, this is the first all-oral, fixed-duration combination regimen approved for this patient group.
- This combination therapy targets two distinct cancer survival pathways: Venetoclax is a BCL-2 inhibitor that restores apoptosis (programmed cell death), while acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks signaling pathways responsible for cancer cell proliferation and survival. - The approval is based on the AMPLIFY trial, where, at a median follow-up of 41 months, the combination reduced the risk of disease progression or death by 35% compared to standard chemoimmunotherapy. - Progression-free survival in the AMPLIFY trial was significantly improved; the estimated 36-month progression-free survival rate was 76.5% for the VENCLEXTA plus acalabrutinib arm versus 66.5% for the chemoimmunotherapy arm. - The regimen is administered for a fixed duration of 14 cycles, with each cycle lasting 28 days, which allows patients a significant period off treatment, contrasting with therapies that are taken continuously until disease progression. - The therapy's safety profile was found to be manageable, with the most common grade 3 or higher adverse event being neutropenia; importantly, a lead-in period with acalabrutinib alone successfully reduced the risk of tumor lysis syndrome (TLS) for most patients before venetoclax was introduced. - This approval marks a collaboration between AbbVie, the manufacturer of VENCLEXTA, and AstraZeneca, which developed acalabrutinib (Calquence). - Economic models suggest that fixed-duration therapies, such as those including venetoclax, may lead to considerable long-term cost savings for healthcare systems compared to continuous treatment regimens.
